Hims & Hers in 2029: Disruptor or Dust? The Next 5 Years Will Decide

Telehealth's golden child faces its make-or-break era.
Growth or stagnation? Here's where the numbers—and the skeptics—say Hims & Hers is headed.
Subheading: The Bull Case: Scaling the 'Healthcare as a Service' Model
Subheading: The Bear Trap: When Investor Patience Runs Thin
Subheading: The Wildcard: Will Big Pharma Crush or Acquire Them?
Closing thought: Either way, Wall Street bankers win—those IPO fees aren't refundable.